my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
03-11-2009: Sanofi-aventis announced that it has entered into an agreement to acquire the company Laboratoire Oenobiol, manufacturer of nutritional, health and beauty supplements. In 2009, Oenobiol had a turnover of 57.2 million Euros, 85% of which was in France and 15% in other countries, primarily in Italy, Spain, Belgium, Poland and Portugal.
"The acquisition of Oenobiol will complete and reinforce our presence on the French market and is fully in line with sanofi-aventis’ strategy to become a global and diversified healthcare leader", declared Nicolas Cartier, General Manager of sanofi-aventis France. "This emblematic brand is well-known and conveys an image of quality and trust, with a strong scientific backing. We are very happy to welcome the women and men of Laboratoire Oenobiol into the sanofi-aventis family, to benefit from their skills while giving them access to sanofi-aventis’ healthcare expertise and development resources" he added.
Dr. Marie Béjot, nutritionist and founder of Laboratoire Oenobiol, will remain highly involved in the strategy and development of the Oenobiol line. She will co-lead a Strategic Committee and a Nutritional Supplement Development Committee within sanofi-aventis.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Oncodesign announced that the company has entered into a strategic research collaboration with Sanofi to apply exclusively Oncodesign’s Nanocyclix(R) technology to several Sanofi kinase target programs. Nanocyclix(R) is a proprietary medicinal chemistry technology and research platform bas ... more
Algeta ASA announced that its research collaboration with Sanofi (previously Genzyme) has been extended. This collaboration, which was announced in April 2011, is focused on evaluating the potential of linking the alpha-emitter thorium-227 to a proprietary antibody from Genzyme to create a ... more
Sanofi Canada invests in prostate cancer research
Sanofi Canada is supporting a five-year study on radiation therapy and prostate cancer. Dr. Tamim Niazi of the Quebec Radiation Oncology GU Group and the JGH is the lead researcher. Sanofi Canada President and CEO, Hugh O'Neill and members of Sanofi's Oncology Team celebrate the collaboration. more
Sanofi-Aventis Deutschland GmbH
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more
Sanofi-Aventis Deutschland GmbH
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more
Sanofi-Aventis Deutschland GmbH
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
